Toll Free: 1-888-928-9744

Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2016

Published: Apr 20, 2016 | Pages: 208 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2016" provides an overview of Cytomegalovirus (HHV-5) Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Cytomegalovirus (HHV-5) Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10 Top Five Countries Contributing to Clinical Trials in Europe 11 Top Countries Contributing to Clinical Trials in North America 12 Top Countries Contributing to Clinical Trials in Middle East and Africa 13 Top Countries Contributing to Clinical Trials in Central and South America 14 Clinical Trials by G7 Countries: Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials 15 Clinical Trials by Phase in G7 Countries 17 Clinical Trials in G7 Countries by Trial Status 18 Clinical Trials by E7 Countries: Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials 19 Clinical Trials by Phase in E7 Countries 20 Clinical Trials in E7 Countries by Trial Status 21 Clinical Trials by Phase 22 In Progress Trials by Phase 23 Clinical Trials by Trial Status 24 Clinical Trials by End Point Status 25 Subjects Recruited Over a Period of Time 26 Clinical Trials by Sponsor Type 27 Prominent Sponsors 28 Top Companies Participating in Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials 29 Prominent Drugs 31 Latest Clinical Trials News on Cytomegalovirus (HHV-5) Infections 32 Feb 21, 2016: Fate Therapeutics to Present Preclinical Data for ProTmune™ at 2016 BMT Tandem Meetings 32 Feb 20, 2016: Chimerix Announces Presentation of Detailed Results From Phase 3 SUPPRESS Trial at BMT Tandem Meetings 32 Clinical Trial Profile Snapshots 35 Appendix 205 Abbreviations 205 Definitions 205 Research Methodology 206 Secondary Research 206 About GlobalData 207 Contact Us 207 Disclaimer 207 Source 208
List of Tables
Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials by Region, 2016* 6 Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8 Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, North America, Top Countries, 2016* 12 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 13 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14 Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 16 Cytomegalovirus (HHV-5) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17 Cytomegalovirus (HHV-5) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18 Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 19 Cytomegalovirus (HHV-5) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20 Cytomegalovirus (HHV-5) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21 Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials by Phase, 2016* 22 Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 23 Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26 Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 27 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31


List of Figures
Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials by Region (%), 2016* 6 Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 13 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14 Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 15 Cytomegalovirus (HHV-5) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 17 Cytomegalovirus (HHV-5) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 18 Proportion of Cytomegalovirus (HHV-5) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 19 Cytomegalovirus (HHV-5) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 20 Cytomegalovirus (HHV-5) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 21 Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials by Phase (%), 2016* 22 Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 23 Cytomegalovirus (HHV-5) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2016* 24 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2016* 25 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 26 Cytomegalovirus (HHV-5) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 27 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29 Cytomegalovirus (HHV-5) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31 GlobalData Methodology 206

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certain

Read More...

Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from main

Read More...

Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in c

Read More...

Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecast

Read More...

Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance driv

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify